RESULTS OF A CLINICAL TRIAL OF A RECOMBINANT VACCINE AGAINST OMICRON-DELTA STRAINS OF SARS-COV-2
DOI:
https://doi.org/10.62209/sewphc/art50122Keywords:
SARS-CoV-2, Omicron-Delta strains, recombinant vaccine, clinical trialAbstract
This paper reports the results of a randomized, blinded, positive-controlled clinical trial to evaluate the immunogenicity and safety of the recombinant novel coronavirus protein vaccine against the Omicron-Delta strains in people aged 18 years and older. A total of 400 volunteers participated in the study, with 150 volunteers each in the experimental and control groups and 100 volunteers in the observation group. The level of neutralizing antibodies in the observation group was significantly higher compared with pre-vaccination 14 days after booster vaccination, demonstrating that vaccination with a single dose of recombinant protein vaccine against Omicron-Delta strains of SARS-CoV-2 for people who have completed full immunization course with the new vaccine against coronavirus mRNA for more than 4 months can also induce the body to create a good humoral immune response against the prototype strain, Delta and Omicron strains (BA.1, BA.4/5). During the research period, all safety assessments performed showed the vaccine to be highly safe. Reported adverse reactions following the vaccine were mild and transient. The use of the highly effective and safe new coronavirus protein vaccine against the Omicron-Delta strains in practical healthcare is promising.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Ўзбекистон Республикаси Санитария-эпидемиология ва жамоат саломатлиги хизмати журнали

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.